| 9.49 -0.7 (-6.87%) | 06-05 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 11.86 |
1-year : | 13.56 |
| Resists | First : | 10.15 |
Second : | 11.6 |
| Pivot price | 9.85  |
|||
| Supports | First : | 7.8 |
Second : | 6.49 |
| MAs | MA(5) : | 10.11 |
MA(20) : | 9.77 |
| MA(100) : | 9.12 |
MA(250) : | 8.18 |
|
| MACD | MACD : | 0.3 |
Signal : | 0.3 |
| %K %D | K(14,3) : | 44.4 |
D(3) : | 51 |
| RSI | RSI(14): 48.8 |
|||
| 52-week | High : | 11.97 | Low : | 6.13 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ NVAX ] has closed above bottom band by 37.7%. Bollinger Bands are 25.8% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 10.2 - 10.29 | 10.29 - 10.35 |
| Low: | 9.06 - 9.18 | 9.18 - 9.25 |
| Close: | 9.35 - 9.55 | 9.55 - 9.67 |
Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical trial; and ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate. It is also developing RSV F vaccine that is in Phase II clinical trial for older adults (60 years and older), as well as that is in Phase I clinical trial for pediatrics. It has a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of NVX-CoV2373, a COVID-19 vaccine candidate. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.
Sat, 06 Jun 2026
Earnings call transcript: Novavax Q1 2026 beats forecasts, stock surges - Investing.com
Fri, 05 Jun 2026
Novavax (NVAX) Up 10.4% Since Last Earnings Report: Can It Continue? - Yahoo Finance
Fri, 05 Jun 2026
Novavax, Inc. (NVAX) is attracting investor attention: Here is what you should know - MSN
Wed, 03 Jun 2026
NVAX Technical Analysis | Trend, Signals & Chart Patterns | NOVAVAX INC (NASDAQ:NVAX) - ChartMill
Mon, 01 Jun 2026
Novavax fireside chat at 2026 Jefferies Global Healthcare Conference - Stock Titan
Tue, 26 May 2026
Novavax, Inc. (NVAX) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 164 (M) |
| Shares Float | 141 (M) |
| Held by Insiders | 5 (%) |
| Held by Institutions | 69.5 (%) |
| Shares Short | 45,280 (K) |
| Shares Short P.Month | 46,340 (K) |
| EPS | -0.57 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -0.8 |
| Profit Margin | -14.8 % |
| Operating Margin | -7.2 % |
| Return on Assets (ttm) | 1.9 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | -79.1 % |
| Gross Profit (p.s.) | 0.99 |
| Sales Per Share | 3.62 |
| EBITDA (p.s.) | 0.36 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -92 (M) |
| Levered Free Cash Flow | 59 (M) |
| PE Ratio | -16.95 |
| PEG Ratio | 1.3 |
| Price to Book value | -12.02 |
| Price to Sales | 2.61 |
| Price to Cash Flow | -17.05 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|